Sovereign Industry Development Fund

Queensland is open for business. The Queensland Government is ready to work with industry on strategic partnership opportunities that will accelerate development in our priority industries of defence, biomedical and biofuels.

For these priority industries, the $180.6 million Sovereign Industry Development Fund will:

  • build our state’s sovereign industry capability
  • draw on our strengths
  • grow all our regions.

About the fund

The fund will initially focus on strategic and catalytic investment partnerships.

Applications closed on 27 February 2026 for feasible, investment-ready projects that:

  • create or significantly expand a sovereign manufacturing or service capability in Queensland, including common-use infrastructure
  • accelerate development in defence, biomedical or biofuels
  • demonstrate a viable pathway to commercial sustainability
  • deliver wider benefits across the industry and Queensland.

Announcements

A competitive assessment process is ongoing with further outcomes to be announced.

  • In late April 2026, the Ampol Renewable Diesel Co Processing Facility became the first project to receive funding under the Queensland Government’s Sovereign Industry Development Fund.

    The Queensland Government has awarded catalytic investment to Ampol’s Lytton refinery to modify its existing facility to co process biogenic feedstocks with conventional diesel and support the growth of Queensland’s biofuels industry.

    The project will increase domestic renewable fuel capability, strengthen fuel security and contribute to emissions reduction in the transport sector.

  • AdvanCell has been awarded funding under the Queensland Government’s Sovereign Industry Development Fund to establish Australia’s first capability to produce Thorium 228, a critical input for next-generation cancer treatments.

    The Queensland Government’s catalytic investment will strengthen Queensland’s position as a global leader in the production of targeted alpha therapies and as one of the only jurisdictions in the world producing Thorim-228 at commercial scale.

    The project will establish new sovereign capabilities for Queensland and accelerate access to life-changing medical treatments.

  • Southern RNA has been awarded funding under the Queensland Government’s Sovereign Industry Development Fund to deliver a new facility capable of fulfilling the final critical stage of conversion from drug substances into patient-ready clinical products, for the first time in Queensland.

    The FlexFill project will establish Queensland’s first semi-automated sterile fill and finish platform, capable of filling up to 2,000 vials per batch and providing an advanced manufacturing solution for therapeutic developers progressing products towards clinical trials.

    The project will build Queensland’s sovereign biomedical manufacturing capabilities and support new opportunities for Queensland’s life sciences industry.

  • Clinical Trials Group has been awarded funding under the Queensland Government’s Sovereign Industry Development Fund to establish a new 40+ bed Phase 1 clinical trials research facility in Eight Mile Plains.

    The purpose-built facility will be able to run 24/7 to deliver first-in-human (FIH) and early-phase clinical trials for the domestic and international biomedical industry, positioning Queensland as a market leader in the clinical trial space.

    The& project will strengthen Queensland’s end to end capability across research, clinical trials, advanced manufacturing and commercialisation.

Guidelines

This fund is just one of the ways we’re helping to deliver a future-ready Queensland.

If you have any enquiries about your application, contact us:

Last updated: 20 May 2026